Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Blood (2025) 146 (Supplement 1): 936.

https://doi.org/10.1182/blood-2025-936

Published: 2025

Journal Articles

Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis

MacKenzie Mayo, Saumya Karne, Hyejeong Jang, Seongho Kim, Jose Maciel Larios, Dipenkumar Modi, Andrew Kin, Lois Ayash, Joseph Uberti, Abhinav Deol

Blood (2025) 146 (Supplement 1): 7832.

https://doi.org/10.1182/blood-2025-7832

Published: 2025

Journal Articles

Race does not impact chimeric antigen receptor T-cell therapy outcomes for multiple myeloma and diffuse large B cell lymphoma

Anisha Rajavel, Sushmitha Nanja Reddy, Saumya Karne, Janaka Liyanage, Seongho Kim, Jose Maciel Larios, Lois Ayash, Dipenkumar Modi, Andrew Kin, Joseph Uberti, Abhinav Deol

Blood (2025) 146 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2025-6327

Published: 2025

Journal Articles

Outcomes of outpatient chimeric antigen receptor T-cell therapy administration: A single center experience at an urban hospital

Anisha Rajavel, Saumya Karne, Sushmitha Nanja Reddy, Janaka Liyanage, Seongho Kim, Jose Maciel Larios, Lois Ayash, Dipenkumar Modi, Andrew Kin, Joseph Uberti, Abhinav Deol

Blood (2025) 146 (Supplement 1): 6329.

https://doi.org/10.1182/blood-2025-6329

Published: 2025

Journal Articles

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Blood (2025) 146 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2025-4232

Published: 2025

Journal Articles

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Manali Kamdar, Julio Chavez, Adam Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Sneha Makadia, Song Pham, Elicia Peneul, Hao Wu, Wahib S. Ead, Iris To, Dennis J. Houston, Connie Lee Batlevi, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2025-3735

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma

Kyle Sugg, Hyejeong Jang, Seongho Kim, Jose Maciel Larios, Andrew Kin, Lois Ayash, Joseph Uberti, Dipenkumar Modi, Abhinav Deol

Blood (2025) 146 (Supplement 1): 7807.

https://doi.org/10.1182/blood-2025-7807

Published: 2025

Journal Articles

Race matters: Cytopenia trajectories after chimeric antigen receptor T- cell therapy in a single-center study

Sushmitha Nanja Reddy, Anisha Rajavel, Saumya Karne, Janaka Liyanage, Seongho Kim, Jose Maciel Larios, Andrew Kin, Lois Ayash, Joseph Uberti, Dipenkumar Modi, Abhinav Deol

Blood (2025) 146 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2025-4170

Published: 2025

Journal Articles

Non-relapse mortality in patients who received CAR T-cell therapy at an urban hospital

Saumya Karne, Anisha Rajavel, Sushmitha Nanja Reddy, Janaka Liyanage, Seongho Kim, Jose Maciel Larios, Lois Ayash, Andrew Kin, Joseph Uberti, Dipenkumar Modi, Abhinav Deol

Blood (2025) 146 (Supplement 1): 4160.

https://doi.org/10.1182/blood-2025-4160

Published: 2025

Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 989.

https://doi.org/10.1182/blood-2024-194581

Published: 2024

Journal Articles

An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Dipenkumar Modi, Jay Yang, Seongho Kim, Asfar Azmi, Emily Tolksdorf, Christiane A. Houde, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 3123.4.

https://doi.org/10.1182/blood-2024-209059

Published: 2024

Journal Articles

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Jeffery J. Auletta, Steven M. Devine, Heather E. Stefanski, Stephen R. Spellman, Todd E. Defor, Brent R. Logan, Brandan J. Butler, Mahasweta Gooptu, Brian C. Shaffer, Antonio M. Jimenez Jimenez, Sameem Abedin, Dipenkumar Modi, MHD Monzr M. Al Malki, Rachel J. Cook

Blood (2024) 144 (Supplement 1): 3514.1.

https://doi.org/10.1182/blood-2024-198252

Published: 2024

Journal Articles

A Phase II Investigator-Initiated Trial of Epcoritamab with Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-Cell Lymphoma

Dipenkumar Modi, Seongho Kim, Mary Domagalski, Varun Mittal

Blood (2024) 144 (Supplement 1): 1742.4.

https://doi.org/10.1182/blood-2024-211276

Published: 2024

Journal Articles

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar N. Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Andre Overesch, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2024-193896

Published: 2024

Journal Articles

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lalita Norasetthada, Joaquin Diaz, Fangfang Lv, Yuqin Song, Seung Tae Lee, Ewa Paszkiewicz-Kozik, Dipenkumar Modi, Armando Santoro, Kumudu Pathiraja, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2024-201522

Published: 2024

Journal Articles

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Jeffery J. Auletta, Monzr M. Al Malki, Todd DeFor, Brian C. Shaffer, Mahasweta Gooptu, Javier Bolanos-Meade, Ramzi Abboud, Adrienne D. Briggs, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Elizabeth J. Shpall, Caitrin Bupp, Stephen R. Spellman, Heather E. Stefanski, Antonio M. Jimenez Jimenez, Steven M. Devine

Blood (2023) 142 (Supplement 1): 780.

https://doi.org/10.1182/blood-2023-172722

Published: 2023

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 613.

https://doi.org/10.1182/blood-2023-174209

Published: 2023

Journal Articles

Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age

Asmita Shukla, Seongho Kim, Hyejeong Jang, Andrew Kin, Aasiya Matin, Lois Ayash, Abhinav Deol, Voravit Ratanatharathorn, Joseph Uberti, Dipenkumar Modi

Blood (2023) 142 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2023-190562

Published: 2023

Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Blood (2023) 142 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2023-188545

Published: 2023

Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song

Blood (2023) 142 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2023-186788

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis

Race does not impact chimeric antigen receptor T-cell therapy outcomes for multiple myeloma and diffuse large B cell lymphoma

Outcomes of outpatient chimeric antigen receptor T-cell therapy administration: A single center experience at an urban hospital

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma

Race matters: Cytopenia trajectories after chimeric antigen receptor T- cell therapy in a single-center study

Non-relapse mortality in patients who received CAR T-cell therapy at an urban hospital

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

A Phase II Investigator-Initiated Trial of Epcoritamab with Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-Cell Lymphoma

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only